How to Do Go-to-Market Research in Financial Services

How to Do Go-to-Market Research in Financial Services

Go-to-market research in financial services is not consumer product research with a compliance overlay. It is a structured evidence-gathering exercise across four groups that can each kill a launch: customers, distributors, regulators, and internal risk owners. The firms that get this right treat GTM research as a sequenced test of assumptions, not a validation exercise for a decision already made.

Here is how to run it properly.

Start with the decision you actually need to make

Most GTM research fails because the brief is too broad. "Should we launch this product?" is not a research question. The useful questions are narrower: what price point holds up under adviser scrutiny, which distribution channel produces acceptable unit economics, which customer segment converts without triggering vulnerability concerns, and whether the regulator will treat this as an existing permission or something new.

Write down the three or four decisions that research must resolve before you can commit capital. Everything else is context.

Map the four stakeholder groups before you speak to anyone

Customers

Segment by regulated status, not marketing persona. A retail customer under Consumer Duty, a sophisticated investor, and a professional client generate entirely different economics and obligations. Your research design must reflect this from the first interview.

Distribution partners

In most financial services launches, the true buyer is not the end customer. It is the IFA network, the wealth platform, the broker, the corporate treasurer, or the introducer. These groups have their own commercial models, PI insurance constraints, and panel governance processes that will shape whether your product ever reaches a customer.

Regulators and supervisors

You are not researching whether the regulator will "approve" the product. You are researching how they will interpret it, which handbook provisions apply, whether it fits existing permissions, and what supervisory attention it will attract in year one.

Internal risk and control functions

Compliance, risk, financial crime, and operations will each apply a veto if the product creates exposures they cannot manage. Treat them as a research subject, not an approval gate at the end.

Sequence the research correctly

Run it in this order:

1. Desk work on regulatory perimeter and precedent. Before any interviews, establish which permissions apply, what similar products exist, and what enforcement or Dear CEO letters have addressed adjacent activity. This shapes every subsequent question.

1. Internal stakeholder interviews. Speak to risk, compliance, and operations early. If they will not support the product as designed, you need to know before you spend money testing customer appetite.

1. Distribution channel research. Test the commercial proposition with the intermediaries who will actually sell or recommend it. This is where most launches quietly die: the product tests well with customers but fails on adviser panels or platform due diligence.

1. Customer research, properly segmented. Only now test pricing, features, and positioning with end customers, using research methods that meet Consumer Duty evidence standards where relevant.

1. Regulator soundings. Time these carefully. Too early and you have nothing concrete to discuss. Too late and you are asking permission rather than testing interpretation.

What most people get wrong

Three recurring mistakes:

Treating regulatory research as a legal opinion. A memo from external counsel is not GTM research. You need direct evidence of how the supervisor thinks, which comes from tracking their public statements, speeches, portfolio letters, and enforcement patterns, and from calibrated conversations with people who have recently engaged with them on adjacent matters.

Confusing distributor politeness with commercial intent. Advisers, platforms, and brokers will tell you a product is "interesting" as a matter of courtesy. Interesting is not a commitment. Test for panel inclusion, minimum volumes, PI treatment, and specific objections. If they cannot articulate why they would replace an incumbent, they will not.

Skipping the internal research. Firms routinely discover in the final approval committee that operations cannot service the product at the assumed cost, or that financial crime has concerns about the customer segment. This should have surfaced in week two.

What good looks like

A GTM research output that a board can act on has three things: a clear view of the commercial case at realistic distribution economics, documented evidence of how each regulated stakeholder group will respond, and a specific list of the assumptions that remain untested and the conditions under which they would break the business case.

Your next decision

Before commissioning any further research, write down the three decisions the work must resolve, and which of the four stakeholder groups you have the weakest evidence on. Start there. Everything else can wait.